Browsing by author "Dearnaley, David"
Now showing items 61-80 of 101
-
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.
Hall, WA; Paulson, E; Davis, BJ; Spratt, DE; Morgan, TM; et al. (ELSEVIER SCIENCE INC, 2021-01-01)PURPOSE: In 2009, the Radiation Therapy Oncology Group (RTOG) genitourinary members published a consensus atlas for contouring prostate pelvic nodal clinical target volumes (CTVs). Data have emerged further informing nodal ... -
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.
Dearnaley, D; Hinder, V; Hijab, A; Horan, G; Srihari, N; et al. (ELSEVIER SCIENCE INC, 2022-03-10)BACKGROUND: Early diagnosis of malignant spinal cord compression (SCC) is crucial because pretreatment neurological status is the major determinant of outcome. In metastatic castration-resistant prostate cancer, SCC is a ... -
Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer.
Lemanska, A; Dearnaley, DP; Jena, R; Sydes, MR; Faithfull, S (ELSEVIER SCIENCE LONDON, 2018-06-01)AIMS: To identify symptom clusters and predisposing factors associated with long-term symptoms and health-related quality of life after radiotherapy in men with prostate cancer. MATERIALS AND METHODS: Patient-reported ... -
Patterns of recurrence after prostate bed radiotherapy.
Brand, DH; Parker, JI; Dearnaley, DP; Eeles, R; Huddart, R; et al. (ELSEVIER IRELAND LTD, 2019-12-01)BACKGROUND AND PURPOSE: Prostate bed radiotherapy is a standard treatment after radical prostatectomy. Recent evidence suggests that, for patients with a PSA > 0.34 ng/ml, the radiotherapy treatment volume should include ... -
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; et al. (ELSEVIER SCIENCE INC, 2017-12-01)PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, ... -
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Denis-Bacelar, AM; Chittenden, SJ; Dearnaley, DP; Divoli, A; O'Sullivan, JM; et al. (SPRINGER, 2017-04-01)PURPOSE: To investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular radiotherapy treatment planning of bone metastases from castration-resistant ... -
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Hafeez, S; Warren-Oseni, K; McNair, HA; Hansen, VN; Jones, K; et al. (ELSEVIER SCIENCE INC, 2016-04-01)PURPOSE: Image guided adaptive radiation therapy offers individualized solutions to improve target coverage and reduce normal tissue irradiation, allowing the opportunity to increase the radiation tumor dose and spare ... -
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; et al. (ELSEVIER SCIENCE BV, 2016-11-01)BACKGROUND: The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen ... -
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos, C; Hutten Selkirk, CG; Saya, S; Bancroft, E; Vertosick, E; et al. (NATURE PUBLISHING GROUP, 2018-03-20)This corrects the article DOI: 10.1038/bjc.2017.429. -
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Rush, HL; Murphy, L; Morgans, AK; Clarke, NW; Cook, AD; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-03-10)PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic ... -
Quality of treatment plans and accuracy of in vivo portal dosimetry in hybrid intensity-modulated radiation therapy and volumetric modulated arc therapy for prostate cancer.
Bedford, JL; Smyth, G; Hanson, IM; Tree, AC; Dearnaley, DP; et al. (ELSEVIER IRELAND LTD, 2016-08-01)BACKGROUND AND PURPOSE: Delivering selected parts of volumetric modulated arc therapy (VMAT) plans using step-and-shoot intensity modulated radiotherapy (IMRT) beams has the potential to increase plan quality by allowing ... -
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; et al. (OXFORD UNIV PRESS INC, 2020-02-01)BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk ... -
Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
Naismith, O; Mayles, H; Bidmead, M; Clark, CH; Gulliford, S; et al. (ELSEVIER SCIENCE LONDON, 2019-09)AIMS: The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was developed ... -
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker, CC; James, ND; Brawley, CD; Clarke, NW; Hoyle, AP; et al. (ELSEVIER SCIENCE INC, 2018-12-01)BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low ... -
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Parker, CC; James, ND; Brawley, CD; Clarke, NW; Ali, A; et al. (PUBLIC LIBRARY SCIENCE, 2022-06-01)BACKGROUND: STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden ... -
Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer.
Tree, A; Dearnaley, D (ELSEVIER SCIENCE BV, 2018-01-01) -
Realizing the potential of magnetic resonance image guided radiotherapy in gynaecological and rectal cancer.
White, IM; Scurr, E; Wetscherek, A; Brown, G; Sohaib, A; et al. (BRITISH INST RADIOLOGY, 2019-05-14)CT-based radiotherapy workflow is limited by poor soft tissue definition in the pelvis and reliance on rigid registration methods. Current image-guided radiotherapy and adaptive radiotherapy models therefore have limited ... -
Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; et al. (ELSEVIER SCIENCE INC, 2020-12-01)PURPOSE: Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of dose to ... -
Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
Aladwani, M; Lophatananon, A; Robinson, F; Rahman, A; Ollier, W; et al. (PUBLIC LIBRARY SCIENCE, 2020-09-17)INTRODUCTION: Previous evidence has suggested a relationship between male self-reported body size and the risk of developing prostate cancer. In this UK-wide case-control study, we have explored the possible association ... -
Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials.
Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; et al. (ELSEVIER IRELAND LTD, 2020-09-01)BACKGROUND AND PURPOSE: This study aimed to identify anatomically-localised regions where planned radiotherapy dose is associated with gastrointestinal toxicities in healthy tissues throughout the pelvic anatomy. MATERIALS ...